Human interferon α1b Inhalation not checked

Kexing Biopharm Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive Human interferon α1b Inhalation Solution”In the company’s words, NCT06363370 on ClinicalTrials.gov
Tested for
Respiratory Syncytial Virus Infections
Main trialPhase 3
“To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.”In the company’s words, NCT06363370 on ClinicalTrials.gov

Other drugs for Respiratory Syncytial Virus Infections

All 20 drugs for Respiratory Syncytial Virus Infections

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jun 2027 Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Human interferon α1b Inhalation

Following is part of Solo: you see every change to Human interferon α1b Inhalation the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in